December 2, 2015

VALUATION WATCH: Overvalued stocks now make up 49.71% of our stocks assigned a valuation and 18.12% of those equities are calculated to be overvalued by 20% or more. Eight sectors are calculated to be overvalued.

Indexing

--ValuEngine Rates and Ranks the NASDAQ

ValuEngine tracks more than 7000 US equities, ADRs, and foreign stock which trade on US exchanges as well as @1000 Canadian equities.  When EPS estimates are available for a given equity, our model calculates a level of mispricing or valuation percentage for that equity based on earnings estimates and what the stock should be worth if the market were totally rational and efficient--an academic exercise to be sure, but one which allows for useful comparisons between equities, sectors, and industries. Using our Valuation Model, we can currently assign a VE valuation calculation to more than 2800 stocks in our US Universe.

We also use trading data to provide forecast estimates for a variety of time horizons for almost ever equity in our database. Our Buy/Sell/Hold recommendations are based upon the 1-year forecast return figure. Using valuation and forecast figures, you can rank and rate our covered stocks against each other, to find out, in an objective and systematic way, the most attractive investment targets based on your own risk/reward parameters. We re-calculate the entire database every trading day, so you are assured that every proprietary valuation and forecast datapoint is as up-to-date as possible.

We can use our data to track individual stocks, industries, sectors, and indices. For today's bulletin, we present key metrics for the top picks in the NASDAQ 100. The companies listed below represent the top-ten STRONG BUY stocks within the index. They are presented below according to their one-month forecast target prices.

Gilead Sciences is the overall leader.

Below is today's data on Gilead Sciences (GILD):

Gilead Sciences, Inc. is an independent biopharmaceutical company that seeks to provide accelerated solutions for patients and the people who care for them. They have a broad-based focus on developing and marketing drugs to treat patients with infectious diseases, including viral infections, fungal infections and bacterial infections, and a specialized focus on cancer. They have expertise in liposomal drug delivery technology, a technology that the company uses to develop drugs that are safer, easier for patients to tolerate and more effective.

VALUENGINE RECOMMENDATION: ValuEngine updated its recommendation from BUY to STRONG BUY for GILEAD SCIENCES on 2015-12-01. Based on the information we have gathered and our resulting research, we feel that GILEAD SCIENCES has the probability to OUTPERFORM average market performance for the next year. The company exhibits ATTRACTIVE Company Size and Sharpe Ratio.

You can download a free copy of detailed report on GILD from the link below.

ValuEngine Forecast
	Target Price*	Expected Return
1-Month	107.00	1.09%
3-Month	109.15	3.12%
6-Month	110.07	3.99%
1-Year	119.71	13.10%
2-Year	111.74	5.56%
3-Year	111.34	5.19%

Valuation & Rankings
Valuation	1.86% undervalued	Valuation Rank(?)	54
1-M Forecast Return	1.09%	1-M Forecast Return Rank	99
12-M Return	5.27%	Momentum Rank(?)	69
Sharpe Ratio	1.38	Sharpe Ratio Rank(?)	99
5-Y Avg Annual Return	35.18%	5-Y Avg Annual Rtn Rank	98
Volatility	25.42%	Volatility Rank(?)	65
Expected EPS Growth	-4.46%	EPS Growth Rank(?)	19
Market Cap (billions)	159.69	Size Rank	100
Trailing P/E Ratio	8.90	Trailing P/E Rank(?)	93
Forward P/E Ratio	9.32	Forward P/E Ratio Rank	84
PEG Ratio	n/a	PEG Ratio Rank	n/a
Price/Sales	5.08	Price/Sales Rank(?)	18
Market/Book	25.28	Market/Book Rank(?)	5
Beta	0.82	Beta Rank	53
Alpha	0.05	Alpha Rank	71

DOWNLOAD A FREE SAMPLE OF OUR GILEAD SCIENCES (GILD) REPORT BY CLICKING HERE
(LINK FIXED)

ValuEngine Market Overview

ValuEngine Sector Overview